OTHER GROUP COMPANIES
market

Zydus Cadila's US arm receives USFDA approval for Eluxadoline Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

November 12, 2021 4:55 IST | India Infoline News Service
Cadila Healthcare
Zydus Cadila, listed as Cadila Healthcare on stock exchanges, on Friday announced that the US-based subsidiary, Zydus Pharmaceuticals (USA) has received tentative approval from the USFDA to market Eluxadoline Tablets in the strengths of 75 mg and 100 mg (US RLD: VIBERZI Tablets). Zydus’ Eluxadoline Tablets are indicated in adults for the treatment of irritable bowel syndrome with diarrhea, or IBS-D.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 324 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

On Sensex, Cadila closed at Rs493 per piece flat compared to the previous closing.

OPEN A DEMAT ACCOUNT & Get FREE Benefits worth 10,000

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Upto 10,000

STOCK VIEW

PRESTIGE (NSE)

The average score for Prestige Estates Projects Limited stands at 4 against 6, three months back.

Prestige Estates Projects Limited is engaged in the business of real estate development. The Company’s principal products/services include Development and construction

FEATURED ARTICLE

BLOGS

Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity